Anthera Pharmaceuticals
Anthera Pharmaceuticals is focused on developing products to treat diseases associated with inflammation and autoimmune diseases.
Launch date
Employees
Market cap
€562k
Enterprise valuation
(€7m) (Public information from Sep 2024)
Share price
$0.0001 ANTH
Hayward California (HQ)
Financials
Estimates*
| EUR | 2015 | 2016 |
|---|---|---|
| R&D budget | 28.0m | 44.0m |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$31.5m | Post IPO Equity | ||
N/A | Post IPO Debt | ||
* | N/A | $47.0m | Post IPO Equity |
$15.0m | Post IPO Equity | ||
$19.0m | Debt | ||
| Total Funding | €50.0m | ||
Related Content
Recent News about Anthera Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.